New learning discoveries about 20327-23-5

The synthetic route of 20327-23-5 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20327-23-5,1-Cyclopropylpiperazine,as a common compound, the synthetic route is as follows.

A mixture of 1-bromo-3-(difluoromethyl)-5-fluoro-benzene (ig, 4.44 mmol) and 1- cyclopropylpiperazine (2.80 g, 22.22 mmol) was microwaved at 200 C for 1 h. Pumped down solvent and purified the crude mixture by ISCO purification (40g silica; 0 % to 5% to 30% of MeOH in DCM) to provide 1-[3-bromo-5-(difluoromethyl)phenyl]piperazine (920 mg, 89%). ?H NMR (300 MHz, CD3OD) oe 7.20 (s, 1H), 7.09 (s, 1H), 7.05 (d, J = 1.0 Hz, 1H), 6.66 (t, J = 56.1 Hz, 1H), 3.20 (dd, J = 6.2, 4.0 Hz, 4H), 2.98 (dd, J = 6.2, 4.1 Hz, 4H) ppm. ESI-MS m/z calc. 290.02, found 291.19 (M+1)+; Retention time: 0.63 minutes., 20327-23-5

The synthetic route of 20327-23-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; DAVIES, Robert, J.; CAO, Jingrong; COCKERILL, Meghan, Elise; COLLIER, Philip, Noel; DENINNO, Michael, Paul; DOYLE, Elisabeth; FRANTZ, James, Daniel; GAO, Huai; GOLDMAN, Brian, Anthony; GREY, Ronald, Lee; GRILLOT, Anne-laure; GU, Wenxin; HENDERSON, James, A.; IRARRAZAVAL, Raul Eduardo, Krauss; KOLPAK, Adrianne, Lynn; LIAO, Yusheng; MAGAVI, Sanjay Shivayogi; MALTAIS, Francois; MESSERSMITH, David; PIERCE, Albert, Charles; PEROLA, Emanuele; RYU, Elizabeth Jin-Sun; SYKEN, Joshua; WANG, Jian; (706 pag.)WO2016/197009; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics